ArticleEuropean heart journal2024
Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥24 h.
Article in European heart journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07713615 (Device-Detected Atrial Fibrillation - Haemostatic Profile and Echocardiographic Variables), which is not on this map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Device-Detected Atrial Fibrillation - Haemostatic Profile and Echocardiographic Variables
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Atrial fibrillation burden in clinical practice, research, and technology development: a clinical consensus statement of the European Society of Cardiology Council on Stroke and the European Heart Rhythm Association.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Guideline
- 2024 Chinese Expert Consensus Guidelines on the Diagnosis and Treatment of Atrial Fibrillation in the Elderly, Endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine (Cardiovascular Branch): Executive Summary.Thrombosis and haemostasis · 2024Guideline
- Anticoagulation in Patients With Device-Detected Atrial Fibrillation With and Without a Prior Stroke or Transient Ischemic Attack: The NOAH-AFNET 6 Trial.Journal of the American Heart Association · 2024Trial
- Closed loop stimulation reduces the incidence of atrial high-rate episodes compared with conventional rate-adaptive pacing in patients with sinus node dysfunctions.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024Trial
- [What to do with device-detected atrial fibrillation? : Executive summary of the position paper of the German Society of Cardiology].Herzschrittmachertherapie & Elektrophysiologie · 2026Review
- Beyond burden metrics: Wearable photoplethysmography-derived spatiotemporal progression of atrial fibrillation linked to clinical outcomes.Heart rhythm O2 · 2026Article
- Subclinical atrial fibrillation: Implications of recent trials for guideline updates?World journal of cardiology · 2026Review
- Recent-onset atrial fibrillation: challenges and opportunities.European heart journal · 2026Review
- Device-detected Atrial Fibrillation: How Much is Too Much?Arrhythmia & electrophysiology review · 2026Review
- Transforming atrial fibrillation management by targeting comorbidities and reducing atrial fibrillation burden: the 10th AFNET/EHRA consensus conference.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Article
- Asia Pacific Heart Rhythm Society (APHRS) scientific statement on stroke prevention strategies in patients with device-detected atrial fibrillation: the 4S-DDAF approach.The Lancet regional health. Western Pacific · 2025Review
- Net Benefit of Anticoagulation in Subclinical Device-Detected Atrial Fibrillation.JAMA network open · 2025Article
- Subclinical atrial fibrillation/atrial high-rate episodes: what significance and decision-making?European heart journal supplements : journal of the European Society of Cardiology · 2025Article
- Evidence Gaps and Lessons in the Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study).Biomedicines · 2025Article
- Refining Stroke Risk Assessment in Patients with Device-Detected Atrial Fibrillation.Journal of clinical medicine · 2024Article
- Device-Detected Atrial Fibrillation and the Impact of Prior Stroke in Stroke Prevention.Journal of the American Heart Association · 2024Article
- Atrial fibrillation burden: a new outcome predictor and therapeutic target.European heart journal · 2024Review
- Great debate: device-detected subclinical atrial fibrillation should be treated like clinical atrial fibrillation.European heart journal · 2024Article
- Screening for atrial fibrillation: the role of CHAEuropean heart journal supplements : journal of the European Society of Cardiology · 2024Article
- Pivotal Trials Testing the Efficacy of Novel Anticoagulants for Preventing Emerging Cardioembolic Risk Entities.Journal of the American Heart Association · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 20 institutions in 17 countries.
Funding
Abstract
BACKGROUND AND
aimsPatients with long atrial high-rate episodes (AHREs) ≥24 h and stroke risk factors are often treated with anticoagulation for stroke prevention. Anticoagulation has never been compared with no anticoagulation in these patients.
methodsThis secondary pre-specified analysis of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High-rate episodes (NOAH-AFNET 6) trial examined interactions between AHRE duration at baseline and anticoagulation with edoxaban compared with placebo in patients with AHRE and stroke risk factors. The primary efficacy outcome was a composite of stroke, systemic embolism, or cardiovascular death. The safety outcome was a composite of major bleeding and death. Key secondary outcomes were components of these outcomes and electrocardiogram (ECG)-diagnosed atrial fibrillation.
resultsMedian follow-up of 2389 patients with core lab-verified AHRE was 1.8 years. AHRE ≥24 h were present at baseline in 259/2389 patients (11%, 78 ± 7 years old, 28% women, CHA2DS2-VASc 4). Clinical characteristics were not different from patients with shorter AHRE. The primary outcome occurred in 9/132 patients with AHRE ≥24 h (4.3%/patient-year, 2 strokes) treated with anticoagulation and in 14/127 patients treated with placebo (6.9%/patient-year, 2 strokes). Atrial high-rate episode duration did not interact with the efficacy (P-interaction = .65) or safety (P-interaction = .98) of anticoagulation. Analyses including AHRE as a continuous parameter confirmed this. Patients with AHRE ≥24 h developed more ECG-diagnosed atrial fibrillation (17.0%/patient-year) than patients with shorter AHRE (8.2%/patient-year; P < .001).
conclusionsThis hypothesis-generating analysis does not find an interaction between AHRE duration and anticoagulation therapy in patients with device-detected AHRE and stroke risk factors. Further research is needed to identify patients with long AHRE at high stroke risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.